ARGENX SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 349.3 EUR | +0.55% |
|
+3.44% | +1.69% |
| Sales 2024 * | 1.71B 1.86B | Sales 2025 * | 2.32B 2.52B | Capitalization | 20.76B 22.59B |
|---|---|---|---|---|---|
| Net income 2024 * | -146M -159M | Net income 2025 * | 167M 182M | EV / Sales 2024 * | 10.7 x |
| Net cash position 2024 * | 2.42B 2.64B | Net cash position 2025 * | 2.54B 2.77B | EV / Sales 2025 * | 7.86 x |
| P/E ratio 2024 * |
-147
x | P/E ratio 2025 * |
123
x | Employees | 1,148 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on argenx SE
More recommendations
More press releases
More news
| 1 day | +0.55% | ||
| 1 week | +3.44% | ||
| Current month | +2.52% | ||
| 1 month | -2.59% | ||
| 3 months | -2.76% | ||
| 6 months | -17.09% | ||
| Current year | +1.69% |
1 week
330.90
350.70
1 month
323.40375.40
Current year
322.50381.10
1 year
271.00494.10
3 years
201.40494.10
5 years
93.05494.10
10 years
6.23494.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 52 | 07-12-31 | |
Karl Gubitz
DFI | Director of Finance/CFO | 54 | 21-05-31 |
Filip Borgions
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 17-04-25 | |
Joseph deBethizy
BRD | Director/Board Member | 74 | 15-05-12 |
Pamela Klein
BRD | Director/Board Member | 63 | 16-04-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.13% | 48 M€ | +9.33% | ||
| 0.93% | 85 M€ | -0.18% | ||
| 0.46% | 17 M€ | +7.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 349.3 | +0.55% | 44,204 |
| 24-06-03 | 347.4 | +1.97% | 32,032 |
| 24-05-31 | 340.7 | +1.04% | 210,405 |
| 24-05-30 | 337.2 | -3.96% | 70,032 |
| 24-05-29 | 351.1 | +3.97% | 102,950 |
Real-time Euronext Bruxelles, June 04, 2024 at 11:35 am EDT
More quotes
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
349.3
EUR
Average target price
436.6
EUR
Spread / Average Target
+24.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.69% | 22.48B | |
| +16.73% | 121B | |
| +13.04% | 107B | |
| -5.80% | 24.82B | |
| -10.09% | 18.32B | |
| -40.52% | 16.33B | |
| -14.00% | 15.31B | |
| +1.18% | 14.08B | |
| +24.18% | 11.74B | |
| +83.67% | 9.02B |
- Stock Market
- Equities
- ARGX Stock
